Neurocast

Neurocast operates at the intersection of digital biomarkers, remote patient monitoring, clinical research, and brain-health technology. Its differentiation is the use of passive, non-invasive signals from ordinary smartphone interactions rather than dedicated hardware or clinic-bound assessments. The Neurocast Platform is designed to collect mental, physical, and social health data during daily life, while Neurocast for Research applies the platform to pharmaceutical trials and academic studies. Neurocast for HCPs & Patients extends the model to ongoing care, and Neurokeys provides a concrete product focused on typing behavior. Relative to conventional neurological testing, the company’s stated advantage is lower participant burden and more continuous observation. Relative to generic remote-monitoring platforms, its specialization is brain health and behavioral signals. Its clinical-trial and medical categories suggest a research-oriented market position, but the absence of disclosed funding, customer metrics, and regulatory detail beyond the reported late-2024 FDA registration limits assessment of commercial scale and competitive durability.

Neurocast’s trajectory shows a progression from platform development toward packaged products and commercial expansion. Founded in 2017 by Erwin Redeman and Levie Hofstee, the company developed a digital brain-health monitoring platform centered on real-world, non-invasive data. Its product portfolio now spans the core Neurocast Platform, Neurocast for Research, Neurocast for HCPs & Patients, Neurokeys, and API and SDK integrations. The reported late-2024 FDA registration and the Sep 10, 2025 rollout of Neurokeys represent the most significant visible product inflection point: the company moved from describing passive monitoring as a platform capability to deploying a specific smartphone-based application that interprets typing behavior. The addition of Adam Deitz as US Commercial Lead on Feb 1, 2026 provides a second expansion signal, suggesting increased attention to US market development. The employee range remains small, with four highlighted current positions and an organization estimate of 11–50 employees. No funding rounds, financing amounts, hiring totals, revenue indicators, or customer growth metrics are publicly reflected in the available profile, so the pace and financial sustainability of expansion cannot be quantified.